Publications

SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells

The radiosensitizing activity of the SMAC-mimetic, Debio 1143, is TNF-alpha-mediated in head and neck squamous cell carcinoma.

Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute…

Phase I Dose-escalation Study with Extended Daily Administration of Debio 1143, an Oral Inhibitor of Apoptosis Protein Inhibitor, in Patients…

Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study

Debio 1143 in combination with carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC)…

Preclinical activity of Debio 1347, an oral selective FGFR1, 2, 3 inhibitor, in models harboring FGFR alterations

Debio 1143, an antagonist of multiple inhibitor-of-apoptosis proteins, activates apoptosis and enhances radiosensitization of non-small cell lung cancer cells in…

A phase I/II randomized study of Debio1143 combined with concurrent chemoradiation therapy (CCRT) in patients with locally advanced squamous cell…